Fri, Nov 28, 2014, 7:33 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

  • kootloops kootloops May 16, 2013 10:46 PM Flag

    Overbought

    Alimera Sciences recently announced that the first patient was treated with Iluvien in Germany. This marks a significant milestone. They also announced the PDUFA date for Iluvien for October of this year. It took a few days, but the share price took off. It went up so much, that I believe it is over-extended and overbought for the current state of affairs. The recent share price appreciation prompted me to rethink my investment in $Alim. I sold my approx. 18000 shares at around $4.50. Don't get me wrong, I still believe Iluvien will do well and will eventually come to market in the United States, however, I feel fair value for the next month or two is around $3.70 - $4.10. Once we start to get some insight from the company on Iluvein sales in the EU and some guidance, the fair value will obviously change. I will be on the sidelines waiting for the next few weeks for the opportunity to re-enter. The market may not agree with me and I may never re-enter. Remember the higher it goes without any news or updates, the more those future announcements are "baked" in to the price.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's not what you were saying in February 2013 Koots .

      I quote you "Currently, ALIM is trading at $2.28 (as of Feb 10th, 2013) and has a market capitalization of $72 million. With over 1 million people in the United States affected by DME at anyone one time, I believe that the market capitalization of Alimera Sciences has the potential to double or even triple in the near term (6 months). Before the previous CRL on November 11, 2011 Alimera's price per share was north of $8. Which is why I believe this stock is a sleeping giant.
      In summary the upcoming catalysts are:
      1. Commercial launch of Iluvien in Germany, UK, etc.
      2. NDA Resubmission to the FDA
      3. Sales of Iluvien in the EU
      4. Marketing authorization in Italy
      5. PDUFA Q3 2013
      6. Possible Iluvien launch in the US Q4 2013
      These are my opinions and my beliefs. I am currently long Alimera Sciences "

      6 months means August 2013 for a triple based on what you write or $ 7 PPS . Now you have made quite an
      about-turn : you have sold ALL your shares.

      Sentiment: Strong Buy

 
ALIM
5.87-0.160(-2.65%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Linn Energy, LLC
NasdaqGSFri, Nov 28, 2014 1:00 PM EST